Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease

Abstract

CSF apoB markedly associates with early tau dysregulation in asymptomatic subjects and identifies at-risk individuals predisposed to develop visuospatial cognitive decline over time.